KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines

[1]  E. Van Cutsem,et al.  Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Bokemeyer,et al.  Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Jonasch,et al.  Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Douillard,et al.  Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC) , 2011 .

[5]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[6]  I. Nagtegaal,et al.  Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. , 2010, European journal of cancer.

[7]  Jiří Drábek,et al.  Clinical Relevance of KRAS in Human Cancers , 2010, Journal of biomedicine & biotechnology.

[8]  Sabine Tejpar,et al.  Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery , 2010, The oncologist.

[9]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Tommasi,et al.  The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma , 2010, Oncology.

[11]  K. Schaefer,et al.  Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.

[12]  O. Myklebost,et al.  Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort , 2010, Genes, chromosomes & cancer.

[13]  A. Bardelli,et al.  Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.

[14]  Sabine Tejpar,et al.  Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.

[15]  G. Fontanini,et al.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.

[16]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[17]  Sanjay Goel,et al.  PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.

[18]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Ferris,et al.  Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. , 2007, Archives of otolaryngology--head & neck surgery.

[20]  U. Dirksen,et al.  Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression , 2007, Journal of Cancer Research and Clinical Oncology.

[21]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[23]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Ychou,et al.  Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray , 2006, Virchows Archiv.

[25]  Yvonne Braun,et al.  Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. , 2006, Neoplasia.

[26]  Sarah Edkins,et al.  Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.

[27]  A. Italiano,et al.  Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Störkel,et al.  Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[31]  T. Kawabe,et al.  Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. , 2003, Cancer research.

[32]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[33]  C. Davis,et al.  Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. , 2001, Critical reviews in oncology/hematology.

[34]  G. Capellá,et al.  K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. , 2000, Cancer research.

[35]  S. Finkelstein,et al.  Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. , 1993, Archives of surgery.

[36]  E. Van Cutsem,et al.  Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Eberlein.  Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab , 2012 .

[38]  F.A.M. Bordonaba,et al.  Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .

[39]  M. Gordon.  Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies , 2008 .